Vanguard Global Advisers
CATX icon

Vanguard Global Advisers’s Perspective Therapeutics CATX Stock Holding History

Vanguard Global Advisers’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Sell
36,489
-37,461
-51% -$142K ﹤0.01% 2690
2026
Q1 		$308K Buy
+73,950
New +$312K ﹤0.01% 2231

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vanguard Global Advisers's CATX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Perspective Therapeutics (CATX) stake by 51% in Q2 2026, selling an estimated $142K and leaving 36,489 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

Vanguard Global Advisers first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $308K in Q1 2026. 129 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Vanguard Global Advisers held 36,489 shares of Perspective Therapeutics worth $124K as of Q2 2026.
  • Vanguard Global Advisers sold 37,461 Perspective Therapeutics shares in Q2 2026, an estimated $142K.
  • Perspective Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2690 holding.
  • Vanguard Global Advisers first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Perspective Therapeutics position peaked at $308K in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.